



Tumor Immunotherapy

Guest Editor:

Dr. Antonino Bruno

1. Laboratory of Immunology and General Pathology, University of Insubria, Varese, Italy
2. Laboratory of Innate Immunity, IRCCS MultiMedica, Milan, Italy

Deadline for manuscript
submissions:

closed (31 October 2021)

Message from the Guest Editor

Dear Colleagues,

Immunotherapy has emerged as the next-generation frontier in cancer treatments, leading to relevant success in diverse cancer types, such as melanoma and lung cancer. Therefore, in this successful scenario, there is still an “unsuccessful” window for some cancer types.

Potential topics for this Issue include, but are not limited to, the following:

- The tumor (immune)-microenvironment as a target for immunotherapy;
- Immune cell polarization and immunotherapy;
- Immune cell angiogenic switch and immunotherapy;
- Molecular pathways in immunotherapy;
- Strategies to re-educate immune cells in cancers;
- Combination therapies acting on the immune system in cancer;
- Delivering strategies in immunotherapy;
- Nanotechnologies in immunotherapy;
- Phytochemicals endowed with immunostimulatory actions for immunotherapy approaches, including vaccines;
- Marine drugs endowed with immunostimulatory actions for immunotherapy approaches, including vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com